Extended showed no clear difference in all‐cause death compared with short‐duration valganciclovir (low certainty).
Extended probably leads to lower CMV syndrome compared with short‐duration valganciclovir (moderate certainty).
Extended may leads to lower CMV infection compared with short‐duration valganciclovir (low certainty).
Extended probably leads to lower acute rejection compared with short‐duration valganciclovir (moderate certainty).
Extended showed no clear difference in opportunistic infections compared with short‐duration valganciclovir (low certainty).
Antiviral prophylaxis leads to lower all‐cause death compared with placebo or no treatment (high certainty).
Extended showed no clear difference in total treatment‐related adverse effects compared with short‐duration valganciclovir (moderate certainty).
Low showed no clear difference in all‐cause death compared with standard dose valganciclovir (low certainty).
Low showed no clear difference in CMV infection compared with standard dose valganciclovir (low certainty).
Low showed no clear difference in acute rejection compared with standard dose valganciclovir (low certainty).
Low showed no clear difference in graft loss compared with standard dose valganciclovir (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Maribavir showed no clear difference in CMV disease compared with ganciclovir (low certainty).
Maribavir showed no clear difference in all‐cause death compared with ganciclovir (low certainty).
Maribavir probably leads to higher CMV infection compared with ganciclovir (moderate certainty).
Antiviral prophylaxis leads to lower CMV infection compared with placebo or no treatment (high certainty).
Maribavir showed no clear difference in acute rejection compared with ganciclovir (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.